The research on Bortezomib, Lenalidomide and Thalidomide is part of his Multiple myeloma project. He performs multidisciplinary study in Internal medicine and Pathology in his work. Pathology and Internal medicine are two areas of study in which he engages in interdisciplinary research. He connects Surgery with Oncology in his research. In his works, Evangelos Terpos undertakes multidisciplinary study on Osteoporosis and Bone disease. Evangelos Terpos undertakes multidisciplinary studies into Immunology and Antibody in his work. Evangelos Terpos combines Antibody and Immunology in his studies. He integrates several fields in his works, including Biochemistry and Enzyme. He conducted interdisciplinary study in his works that combined Enzyme and Biochemistry.
Internal medicine is intertwined with Oncology, Surgery, Gastroenterology, Pathology and Endocrinology in his research. In his papers, he integrates diverse fields, such as Pathology and Internal medicine. His Multiple myeloma study combines Bortezomib and Lenalidomide studies. In his works, Evangelos Terpos undertakes multidisciplinary study on Immunology and Antibody. He connects Antibody with Immunology in his study. He conducts interdisciplinary study in the fields of Osteoporosis and Bone disease through his works. In his research, he undertakes multidisciplinary study on Bone disease and Osteoporosis. He combines Bone marrow and Multiple myeloma in his research.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade.
Lancet Oncology (2014)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie.
Lancet Oncology (2016)
Hematological findings and complications of COVID-19.
Evangelos Terpos;Ioannis Ntanasis-Stathopoulos;Ismail Elalamy;Efstathios Kastritis.
American Journal of Hematology (2020)
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
Amy V. Jones;Sebastian Kreil;Katerina Zoi;Katherine Waghorn.
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
P. Moreau;J. San Miguel;P. Sonneveld;M. V. Mateos.
Annals of Oncology (2010)
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
Antonio Palumbo;Sara Bringhen;Maria Victoria Mateos;Alessandra Larocca.
Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid
M. A. Dimopoulos;E. Kastritis;C. Bamia;I. Melakopoulos.
Annals of Oncology (2009)
Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group
Meletios A. Dimopoulos;Evangelos Terpos;Asher Chanan-Khan;Nelson Leung.
Journal of Clinical Oncology (2010)
Soluble receptor activator of nuclear factor κB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index
Evangelos Terpos;Richard Szydlo;Richard Szydlo;Jane F. Apperley;Jane F. Apperley;Evdoxia Hatjiharissi;Evdoxia Hatjiharissi.
Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid
Meletios A Dimopoulos;Efstathios Kastritis;Athanasios Anagnostopoulos;Ioannis Melakopoulos.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: